| Status | Discontinued |
| Process | STA pre-2018 |
| Referral date | 01 December 2007 |
| Topic area |
|
| Description |
Please refer to Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor). |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting | TBC |
Project Team
| Communications manager: | Sarita Tamber |
| Executive Lead: | Gillian Leng |
| Project manager: | Bijal Joshi |
| Technical Lead: | Scott Goulden |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 August 2009 |
Further to the Scoping Workshop, lapatinib for the first-line treatment of metastatic hormone-sensitive breast cancer has been temporarily suspended. Following discussion of the comments received during the scoping exercises/workshop, we are liaising with the Department of Health for confirmation that lapatinib is appraised alongside trastuzumab, in a Multiple Technology Appraisal. When further details are available, the website will be updated. |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance